您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > JAK1/TYK2-IN-3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
JAK1/TYK2-IN-3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
JAK1/TYK2-IN-3图片
CAS NO:2734918-37-5
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
JAK1/TYK2-IN-3 是一种有效的,选择性和口服活性的双重TYK2/JAK1抑制剂,IC50值分别为 6 和 37 nM。JAK1/TYK2-IN-3 选择性的作用于JAK2(IC50=140 nM) 和JAK3(IC50=362 nM)。JAK1/TYK2-IN-3 通过调节TYK2/JAK1相关基因的表达以及 Th1 、Th2 和 Th17 细胞的形成来发挥抗炎作用。
生物活性

JAK1/TYK2-IN-3 is a potent, selective and orally active dualTYK2/JAK1inhibitor withIC50values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative toJAK2(IC50=140 nM) andJAK3(IC50=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of relatedTYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells[1].

IC50& Target

Tyk2

6 nM (IC50)

JAK1

37 nM (IC50)

JAK2

140 nM (IC50)

JAK3

362 nM (IC50)

体外研究
(In Vitro)

JAK1/TYK2-IN-3 (compound 48) (10, 20, 30 mg/kg) shows anti-inflammatory effect by regulating the formation of Th1, Th2, Th17 cells[1].
JAK1/TYK2-IN-3 (10, 20, 30 mg/kg) inhibits the NF-κB signaling pathway by inhibits the JAK-STAT pathway, thereby reducing the inflammatory response in ulcerative colitis (UC) mice[1].
JAK1/TYK2-IN-3 (10, 20, 30 mg/kg) dose-dependently inhibits the mRNA expression of TNF-α, IL-1β, IL-12, IL-17A, IL-22, IFN-α, and IFN-β[1].

体内研究
(In Vivo)

JAK1/TYK2-IN-3 (10, 20, 30 mg/kg; p.o.; twice a day for 12 days) shows a good therapeutic effect on ulcerative colitis (UC)[1].
JAK1/TYK2-IN-3 (5 mg/kg, p.o.) shows 23.7% oral bioavailability in rats[1].
Pharmacokinetic Parameters of JAK1/TYK2-IN-3 in male Sprague-Dawley rats[1].

compddose(mg/kg)AdministrationCmax(ng/mL)Cl (Lh-1kg-1)T1/2(h)AUC0-t(ng·h/mL)F (%)
485 mg/kgp.o.400.4±55.311.3±5.22.4±2.1440.9±157.023.7

Animal Model:6-8 weeks, 270-325g male Sprague-Dawley rats[1]
Dosage:5 mg/kg
Administration:p.o.
Result:Showed 23.7% oral bioavailability in rats.
Animal Model:Six-eight week old male C57BL/6 mice, 20-22 g (2.5% dextran sulfate sodium (DSS)-induced acute UC mouse model)[1]
Dosage:10, 20, 30 mg/kg
Administration:p.o., twice a day, 12 days
Result:Improved the infiltration of inflammatory factors and reduced the damage caused by DSS.
分子量

377.39

Formula

C17H21F2N7O

CAS 号

2734918-37-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.